Oct 12, 2023 · 56m · capital-allocators
Finny Kuruvilla – The Fourth Source of Alpha at Eventide (EP.343)
0:00 / 0:00
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In Episode 343 of Capital Allocators, host Ted Seides interviews Finny Kuruvilla, Co-CIO of Eventide Asset Management, exploring his transition from clinical medicine to fund management and how Eventide pairs rigorous scientific diligence with a values-based framework to capture 'values-driven alpha.'
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Ted holds 11.2% of the talking time here. How this is scored →
Ted as informed peer 1.6 Guest teaching 3.5 Guest disagreement 0.8 Ted pushing back 0.2
speaking balance: gold is Ted, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 22:15 Finny dismantles mainstream ESG scoring absurdities
Finny criticizes mainstream ESG methodology, pointing out the lack of common sense when tobacco manufacturers receive higher ratings than companies curing lung cancer.
Hardest push from Ted ▶ 40:30 Ted challenges ethical pricing within cutthroat market competitionTed directly asks how a values-driven company can survive when competitors maximize short-term pricing power and consumer extraction.
Biggest teaching moment ▶ 30:50 Finny expands Russell Fuller's alpha taxonomy to include values-driven alphaFinny walks through the informational, analytical, and behavioral alpha frameworks before introducing a documented 3% annualized values-based alpha that standard models miss.
Ted holds their own ▶ 40:30 Ted probes the operational tension between ethics and competitive pricingTed displays his allocator insight by pressing on whether ethical restraint disadvantages firms when competing head-to-head against aggressive market participants.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | Ted as informed peer | Guest teaching | Guest disagreement | Ted pushing back | Why |
|---|---|---|---|---|---|---|
| Finny Kuruvilla's Background, Education, and Early Market Fascination | 1 | 2 | 0 | 0 | Ted opens with standard biographical prompts regarding Finny's upbringing and academic path. Finny shares his background as an immigrant's son and how reading Peter Lynch during his MD-PhD led him to investing. | |
| The Decision to Pivot from Clinical Medicine to Biotechnology | 1 | 3 | 0 | 0 | Ted asks why Finny chose investing over clinical practice. Finny explains the repetitive nature of clinical practice versus the broader systemic impact possible through biotech drug development. | |
| Launching Eventide Asset Management and Early Firm Growth | 1 | 2 | 0 | 0 | Finny details his entry into venture capital at Claris Ventures and the parallel launch of Eventide in 2008 with $100,000 in seed capital. | |
| The Love Your Neighbor Values Framework and Six Stakeholders | 1 | 4 | 1 | 0 | Finny lays out Eventide's foundational philosophy, articulating the 'love your neighbor' principle and the CES-squared framework across six stakeholders. | |
| Critiquing Mainstream ESG and Defining Value in Healthcare | 2 | 5 | 3 | 0 | Finny takes aim at mainstream ESG metrics, pointing out absurdities like tobacco companies outranking cancer therapeutics, and differentiates genuine healthcare innovation from me-too vanity drugs. | |
| The Avoid, Embrace, Engage Framework and Biotech Diligence | 2 | 4 | 0 | 0 | Finny outlines the Avoid, Embrace, Engage methodology and explains why rigorous clinical science and due diligence are necessary to handicap biotech trial odds. | |
| Target Market Sweet Spots and the Fourth Source of Alpha | 2 | 4 | 1 | 0 | Finny describes identifying secular growth themes that advance human flourishing and introduces values-driven alpha as the overlooked fourth source of alpha alongside Russell Fuller's three traditional sources. | |
| Assessing Executive Integrity, Avoiding Charisma, and Portfolio Sizing | 2 | 4 | 2 | 0 | Finny warns against relying on charismatic CEO presentations and shallow analyst impressions, detailing how Eventide independently reconstructs data to test management integrity and calibrates position sizing around binary risk. | |
| Shareholder Stewardship, RAISE Framework, and the Merck Ivermectin Case | 3 | 4 | 1 | 2 | Ted presses Finny on how companies that refrain from price-gouging stay competitive against ruthless peers. Finny responds using Merck's distribution of ivermectin for river blindness as a case study for long-term reputational compounding. | |
| Internal Culture and Expanding the Values-Based Investing Movement | 1 | 3 | 0 | 0 | Finny explains Eventide's hiring strategy focused on mission alignment over mercenary compensation, and outlines his vision for expanding values-based capital allocation across the broader market. |
Statements from this episode (17)
Kuruvilla: Deep domain expertise provides the real edge against Wall Street
“The basic line that Peter Lynch hammers home is that there's a few disciplines you need to learn in terms of accounting and some basic knowledge about investing, but the real edge that you can have to beat Wall Street is if you have deep domain expertise in a …”
Kuruvilla: Childhood leukemia survival rates rose from ~10% in 1970 to ~90% today
“If you had a child in 1970 with leukemia, he or she would have about a 10% chance of making to adulthood. So pretty grim odds. Today, if you have a child with leukemia, He or she will have closer to a 90% chance of making to adulthood, so a complete reversal i…”
Kuruvilla: Biotech innovators can impact 10x-100x more patients than individual clinicians
“If you want to really be able to maximize your ability to affect patients, Then moving over to something on the, say the biotech or pharmaceutical side, you're actually more likely to have a shot to actually impact an order of magnitude or two more than you wo…”
Kuruvilla: Eventide launched in July 2008 on $800K friends-and-family capital
“Went around to, as I said, friends and family and raised about 800,000 dollars of just business capital to get the company going. And we launched Eventide in the summer of 2008. Our mutual fund opened up in July of 2008.”
Kuruvilla: Eventide evaluates six internal and external stakeholders using CES-squared framework
“We have made the case that each business has fundamentally six neighbors or six stakeholders, and it's easy to remember. We have this acronym CES squared. There's three internal and three external stakeholders. So the three internal are customers, employees, a…”
Kuruvilla: Multi-stakeholder value-creating businesses outperform purely financial-focused companies long-term
“The thesis is that those types of businesses that are creating value for its stakeholders will outperform over the long haul in general, those businesses that are focusing only on one form of capital, i.e. Financial capital.”
Kuruvilla: Philip Morris rates higher in ESG databases than lung cancer drugmakers
“So we have often marveled that Philip Morris, which is a widely known provisioner of cigarettes and tobacco, rates more highly on many of these databases than on companies that are actually trying to treat lung cancer.”
Kuruvilla: Much of biotech makes minor drug tweaks to charge $300k
“Okay, so a lot of biotech, unfortunately, is based on taking something that's already out there and tweaking it very, very slightly, changing a few atoms here and there in order to get a patent worth 20 years of life, and then going to market there with an inc…”
Kuruvilla: Eventide avoids me-too drugs and vanity aesthetics like Botox variants
“We tend to be less interested in these Me Too's, these slight tweaks here and there. We're also less interested in products that are gonna be just pandering to aspects of human vanity. There's this whole aspect of aesthetics, which it's just somebody selling a…”
Kuruvilla: Phase 3 clinical trials have roughly a 50% success rate
“It's roughly a flip of the coin at a phase three study.”
Kuruvilla: A 10% edge in biotech trial forecasting creates outsized alpha
“It's the same thing in our field here, where if you can be even 10% better than the average, then you're going to be an all star because these events tend to be so Dramatic. So companies can go up two or three fold, a hundred percent, 200% moves overnight, or …”
Kuruvilla: Studies suggest values-driven investing yields 3% annualized alpha
“I think the best studies out there would suggest that there's somewhere in the neighborhood of three percent annualized alpha that the market hasn't captured while controlling for size and market cap and all the standard factors there that is to be harvested.”
Kuruvilla: Executive charm and eloquence do not correlate with business competence
“And that feeling is a complicated result of charm, beauty, eloquence, all these factors that don't really, in the end, correlate very well to are they a great business person or not.”
Kuruvilla: Public equity investing confers ethical responsibility for corporate actions
“Investing is ownership. Investing confers an ethical responsibility To the owner for the activities of the firm.”
Kuruvilla: Recruiting on pay over mission creates mercenaries who jump firms
“One of the things that I think is so important is that you want to hire people for mission fit and for mission alignment much more so than recruit people on financial generosity or something like that. You can do that, but in the end, what you're going to have…”
Kuruvilla: Under 1% of religious investors' assets use values frameworks
“So right now, if you look at the percentage of assets that people have who are religious or values-inclined, frameworks like that, it's certainly less than one percent.”
Kuruvilla: True diligence requires in-person meals with founders and their associates
“If you really want to diligence somebody well, learn how to go out to lunch and dinner with not just that person, but the associates of those people to really understand who they are. It's amazing what you can learn over a meal that you wouldn't learn over Zoo…”